Pfizer Inc (PFE) 30.55 $PFE
Eli Lilly and Immunocore Collaborate to Develop Cancer Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 3:30PM CDT
Eli Lilly and Company (LLY) entered into an agreement with privately held Immunocore Limited for the research and development of new T cell-based cancer treatments.
Pfizer Eyes InnoPharma, Acquisition to Boost Injectables Biz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 2:40PM CDT
Pfizer's (PFE) acquisition of InnoPharma, slated to close in the third quarter, could see the company shelling out up to $360 million.
Research and Markets: Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
Business Wire - Thu Jul 17, 1:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9d5hv/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering.
Most active New York Stock Exchange-traded stocks
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
White House Push to Stop U.S. Companies Moving Overseas Unlikely to Bear Fruit
at The Street - Thu Jul 17, 11:50AM CDT
The administration's push to stop so-called corporate 'inversions' appears aimed at motivating the Democratic base ahead of midterm elections.
Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
M2 - Thu Jul 17, 10:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8lcbs/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering. This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market. The launch of high-cost GnRH antagonist therapies such as AbbVie's Elagolix (which is in phase III trial) is expected during the forecast period. Currently, the market is being served by low-cost alternatives such as combined OCPs, NSAIDs, and progestins. Patients tend to choose low-cost alternatives, which will be a challenge to the high-cost GnRH Antagonist market. According to the report, the Global Endometriosis market is driven by a large amount of unmet need due to lack of diagnostics and lack of approved treatment options for the disease. Currently, the diagnosis is mainly through non-invasive methods where standard diagnostic procedures are not available. Thus, development of proper diagnostic tools for the early detection of the disease will increase the number of patients treated. A lack of approved drugs for the treatment of endometriosis creates a lucrative space for companies to develop new therapy options to enter the market. Further, the report states that one of the main challenges is patent expiries of endometriosis drugs which leads to loss of exclusive rights of branded products followed by the introduction of low-priced generics into the market. This poses a potential threat to the established companies that spend a huge amount on R&D. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Abbvie Inc. - AstraZeneca plc - Bayer AG - Pfizer Inc. Other Prominent Vendors - Astellas Pharma Inc. - Abbvie Inc. - Repros Therapeutics Inc. - Sanofi SA - Takeda Pharmaceuticals Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Market Segmentation by Route of Administration and Type of Dosage Form - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/k8lcbs/global
Cramer: The Tell of When to Sell
at The Street - Thu Jul 17, 9:40AM CDT
If you're worried about these moves, it's time to cash out.
Early Glance: Pharmaceuticals companies
AP - Thu Jul 17, 9:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Pfizer Bolsters Injectables by Buying InnoPharma
at The Street - Thu Jul 17, 9:17AM CDT
Fresh from AstraZeneca plc's rebuff of its $117 billion offer, Pfizer is setting its sights on a much smaller deal in the U.S. by acquiring InnoPharma.
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis(R) (apixaban) in Patients with NVAF Undergoing Cardioversion
Business Wire - Thu Jul 17, 7:06AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE
FE) today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Eliquis is currently approved to reduce the risk of stroke and systemic embolism in patients with NVAF. Cardioversion (administered through electric shock to the chest or with medication) is a commonly used, effective method of converting atrial fibrillation to a normal rhythm, allowing the heart to pump more effectively. Traditionally, anticoagulation is administered for a minimum of three weeks prior to cardioversion and for four weeks afterward. In some patients, early cardioversion can be performed on the same day or within days of new-onset NVAF, usually after imaging, to confirm the absence of a pre-existing thrombus in the heart, which could be dislodged during the cardioversion procedure and cause a stroke.
Genentech Alzheimer's drug misses goals in studies
By MARILYNN MARCHIONE - AP - Wed Jul 16, 5:57PM CDT
An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.
Pfizer Set to Possibly Pullback After Yesterday's Rally of 1.81%
Comtex SmarTrend(R) - Wed Jul 16, 4:21PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $30.37 to a high of $30.97. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $30.62 on volume of 32.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Pfizer (PFE) Stock Is Up Today
at The Street - Wed Jul 16, 11:58AM CDT
Pfizer (PFE) rose Wednesday after the pharmaceutical giant said its drug BeneFIX reached its primary endpoint in a Phase 3 trial.
#FOGO? - New Survey Reveals 87% of Americans have a Fear of Getting Old (FOGO) - Results Show Top Fear is Decline in Physical Ability(1)
Business Wire - Wed Jul 16, 9:00AM CDT
--New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 2013(2)
Pfizer to Acquire InnoPharma, Inc.
Business Wire - Wed Jul 16, 8:26AM CDT
--Portfolio of 10 Approved Products and Pipeline of More Than 30 Products in Development; 19 Pending Approval with the United States Food and Drug Administration
Top Stocks to Watch Today: St. Jude Medical, Abbott Laboratories, Eli Lilly, Pfizer
Leo Sun, The Motley Fool - Motley Fool - Wed Jul 16, 7:57AM CDT
Let's take a quick look at four stocks -- St. Jude Medical , Abbott Laboratories , Eli Lilly , and Pfizer -- which could loom large in health care headlines this Wednesday morning. St. Jude Medical beats estimates for the second quarter ...
Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
Eli Lilly and Immunocore Collaborate to Develop Cancer Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 3:30PM CDT
Eli Lilly and Company (LLY) entered into an agreement with privately held Immunocore Limited for the research and development of new T cell-based cancer treatments.
Pfizer Eyes InnoPharma, Acquisition to Boost Injectables Biz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 2:40PM CDT
Pfizer's (PFE) acquisition of InnoPharma, slated to close in the third quarter, could see the company shelling out up to $360 million.
Research and Markets: Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
Business Wire - Thu Jul 17, 1:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9d5hv/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering.
Most active New York Stock Exchange-traded stocks
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
White House Push to Stop U.S. Companies Moving Overseas Unlikely to Bear Fruit
at The Street - Thu Jul 17, 11:50AM CDT
The administration's push to stop so-called corporate 'inversions' appears aimed at motivating the Democratic base ahead of midterm elections.
Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
M2 - Thu Jul 17, 10:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8lcbs/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering. This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market. The launch of high-cost GnRH antagonist therapies such as AbbVie's Elagolix (which is in phase III trial) is expected during the forecast period. Currently, the market is being served by low-cost alternatives such as combined OCPs, NSAIDs, and progestins. Patients tend to choose low-cost alternatives, which will be a challenge to the high-cost GnRH Antagonist market. According to the report, the Global Endometriosis market is driven by a large amount of unmet need due to lack of diagnostics and lack of approved treatment options for the disease. Currently, the diagnosis is mainly through non-invasive methods where standard diagnostic procedures are not available. Thus, development of proper diagnostic tools for the early detection of the disease will increase the number of patients treated. A lack of approved drugs for the treatment of endometriosis creates a lucrative space for companies to develop new therapy options to enter the market. Further, the report states that one of the main challenges is patent expiries of endometriosis drugs which leads to loss of exclusive rights of branded products followed by the introduction of low-priced generics into the market. This poses a potential threat to the established companies that spend a huge amount on R&D. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Abbvie Inc. - AstraZeneca plc - Bayer AG - Pfizer Inc. Other Prominent Vendors - Astellas Pharma Inc. - Abbvie Inc. - Repros Therapeutics Inc. - Sanofi SA - Takeda Pharmaceuticals Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Market Segmentation by Route of Administration and Type of Dosage Form - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/k8lcbs/global
Cramer: The Tell of When to Sell
at The Street - Thu Jul 17, 9:40AM CDT
If you're worried about these moves, it's time to cash out.
Early Glance: Pharmaceuticals companies
AP - Thu Jul 17, 9:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Pfizer Bolsters Injectables by Buying InnoPharma
at The Street - Thu Jul 17, 9:17AM CDT
Fresh from AstraZeneca plc's rebuff of its $117 billion offer, Pfizer is setting its sights on a much smaller deal in the U.S. by acquiring InnoPharma.
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis(R) (apixaban) in Patients with NVAF Undergoing Cardioversion
Business Wire - Thu Jul 17, 7:06AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE
FE) today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Eliquis is currently approved to reduce the risk of stroke and systemic embolism in patients with NVAF. Cardioversion (administered through electric shock to the chest or with medication) is a commonly used, effective method of converting atrial fibrillation to a normal rhythm, allowing the heart to pump more effectively. Traditionally, anticoagulation is administered for a minimum of three weeks prior to cardioversion and for four weeks afterward. In some patients, early cardioversion can be performed on the same day or within days of new-onset NVAF, usually after imaging, to confirm the absence of a pre-existing thrombus in the heart, which could be dislodged during the cardioversion procedure and cause a stroke. Genentech Alzheimer's drug misses goals in studies
By MARILYNN MARCHIONE - AP - Wed Jul 16, 5:57PM CDT
An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.
Pfizer Set to Possibly Pullback After Yesterday's Rally of 1.81%
Comtex SmarTrend(R) - Wed Jul 16, 4:21PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.37 to a high of $30.97. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $30.62 on volume of 32.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. Why Pfizer (PFE) Stock Is Up Today
at The Street - Wed Jul 16, 11:58AM CDT
Pfizer (PFE) rose Wednesday after the pharmaceutical giant said its drug BeneFIX reached its primary endpoint in a Phase 3 trial.
#FOGO? - New Survey Reveals 87% of Americans have a Fear of Getting Old (FOGO) - Results Show Top Fear is Decline in Physical Ability(1)
Business Wire - Wed Jul 16, 9:00AM CDT
--New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 2013(2)
Pfizer to Acquire InnoPharma, Inc.
Business Wire - Wed Jul 16, 8:26AM CDT
--Portfolio of 10 Approved Products and Pipeline of More Than 30 Products in Development; 19 Pending Approval with the United States Food and Drug Administration
Top Stocks to Watch Today: St. Jude Medical, Abbott Laboratories, Eli Lilly, Pfizer
Leo Sun, The Motley Fool - Motley Fool - Wed Jul 16, 7:57AM CDT
Let's take a quick look at four stocks -- St. Jude Medical , Abbott Laboratories , Eli Lilly , and Pfizer -- which could loom large in health care headlines this Wednesday morning. St. Jude Medical beats estimates for the second quarter ...
Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
